PER-001-04已完成未知
INTERNATIONAL MULTICENTER STUDY, DOUBLE-BLIND, RANDOMIZED, PHASE III OF SATRAPLATIN PLUSBO PLUSBO OR PREDNISONE PLUSBO IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER PREVIOUSLY TREATED WITH A REGIME OF CYTOXIC CHEMOTHERAPY GPC SAT3-03-01
GPC BIOTECH INC.,0 个研究点目标入组 0 人开始时间: 2004年3月4日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Metastatic prostate cancer in stage D2
- •Progression after previous chemotherapy
- •ECOG performance status equal / less than 2
- •Life expectancy> 3 months
- •Surgical or medical castration
- •Adequate functions of bone marrow, liver and kidney
- •Informed consent
排除标准
- •More than one prior chemotherapy
- •Previous compounds containing platinum
- •Previous malignancy
- •Previous RT / radionuclide therapy
- •Major surgery GI or GI disease that affects absorption
- •Disease with contraindication for steroids
- •Brain metastasis
研究者
相似试验
已完成
不适用
INTERNATIONAL STUDY, MULTICENTRIC, STRATIFIED, RANDOMIZED, DOUBLE-BLIND, WITH PLACEBO OVERLOAD, IN PARALLEL GROUPS, DURING 52 WEEKS OF GASTROINTESTINAL CLINICAL SECURITY, TO DEMONSTRATE THAT COX189 (400 MG / DAY OD) REDUCES THE RISK OF DISREGARDING COMPLICATED ULCERS COMPARING WITH NSAIDS (NAPROXENO 500 MG, BID AND IBUPROPHENE 800MG.ID) IN PATIENTS WITH OSTEOARTHRITIS, COX STUDY 1189 TARGET PART IIPER-022-02OVARTIS BIOSCIENSES PERU S.A.,
尚未招募
3 期
A Study to compare the efficacy and safety of PZN-128 in treatment chronic idiopathic thrombocytopenic purpura.CTRI/2023/10/058677PHARMASYNTEZ-NORD JSC
已完成
不适用
An international multi-centre, randomised, double-blind, placebo controlled trial to evaluate the efficacy and safety of 0.5% and 2% Pro 2000/5 gels for the prevention of vaginally acquired human immunodeficiency virus (HIV) infectionsHIVInfections and InfestationsHuman immunodeficiency virus (HIV)ISRCTN64716212Medical Research Council (MRC) (UK)9,673
进行中（未招募）
1 期
Radioimmunotherapy with 90Y-Clivatizumab Tetraxetan plus Low Dose Gemcitabine versus Placebo plus Low-Dose GemcitabineMetastatic (Stage IV) Pancreatic AdenocarcinomaMedDRA version: 19.0Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864EUCTR2013-004516-21-ATImmunomedics, Inc.333
进行中（未招募）
1 期
Radioimmunotherapy with 90Y-Clivatizumab Tetraxetan plus Low Dose Gemcitabine versus Placebo plus Low-Dose GemcitabineEUCTR2013-004516-21-BEImmunomedics, Inc.440